SHUN-FA YANG2026-10-162026-10-162025-07-01Pure ID: 15146272Pure UUID: 92effff0-ff49-4973-b00e-589074bca70310.1002/dmrr.70058https://www.scopus.com/pages/publications/105007614239https://scholars.csmu.edu.tw/handle/123456789/26663Aims: Type 2 diabetes mellitus (T2DM) is recognized for increasing the risk of dementia; however, conclusive evidence supporting interventions to mitigate this risk remains elusive. This study endeavours to ascertain whether the glucagon-like peptide-1 receptor agonists (GLP-1RAs) correlate with reduced incidence of dementia. Materials and Methods: The cohort comprised individuals initiating treatment with either GLP-1RAs or non-GLP-1RAs medications between 2013 and 2021. This study examined the association between GLP-1RAs and the risk of all-cause dementia. Propensity score-matched and Cox proportional hazard models were employed to calculate the adjusted hazard ratio (aHR) and confidence interval (CI) for the incidence of dementia. Results: Among a cohort comprising 109,778 individuals, the use of GLP-1RA demonstrated a reduced risk of dementia compared with its non-use (aHR, 0.90; 95% CI, 0.83–0.97). Subgroup analyses stratified by different diabetic complications revealed significantly lower dementia incidence rates among GLP-1RAs users than among non-GLP-1RAs users. Individuals aged ≤ 75 years demonstrated a significant protective effect within GLP-1RAs users. Conclusions: The utilization of GLP-1 receptor agonists instead of non-GLP-1RAs medications demonstrated an association with a decreased incidence of dementia.enImpact of Glucagon-Like Peptide-1 Receptor Agonists on the Dementia Incidence in Patients With Type 2 Diabetes MellitusA Population-Based Longitudinal Cohort Studyjournal article